To evaluate the comparative study of sackubactrivalsartan and amlodipine besylate on vascular remodeling in patients with hypertension.Compared with amlodipine, sacubatrotrivalsartan can effectively improve vascular endothelial function and arterial stiffness in hypertensive patients and delay the progression of atherosclerosis.

A total of 200 hypertensive patients admitted to the Department of Cardiology of our hospital from April 2022 to April 2024 were selected and divided into treatment group (n=100) and control group (n=100) by random number table method. The case group was treated with sakubactril valsartan sodium tablets, the initial dose was 100mg, once a day, after 2 weeks, the blood pressure was not up to the standard can be increased to 200mg, once a day, the maximum dose is not more than 400mg, once a day. The control group was treated with amlodipine besylate, the initial dose was 5mg once a day, the dose was adjusted according to the control of blood pressure, the maximum dose was not more than 10mg once a day. Both groups can be combined with other antihypertensive drugs when necessary. Blood pressure (systolic blood pressure, diastolic blood pressure, pulse pressure difference), pulse wave conduction velocity (PWV), ankle-brachial index (ABI), arteriosclerosis index and pulse pressure index were observed before treatment, 2 weeks, 4 weeks, 12 weeks and 24 weeks after treatment.

After 2 weeks of treatment, the blood pressure indexes of both groups decreased from the baseline level, but the difference was not statistically significant (P>0.05). After 4 and 12 weeks of treatment, the diastolic blood pressure in the case group was significantly lower than that in the control group (P<0.05), but there was no statistical significance in systolic blood pressure and pulse pressure difference (P>0.05). After 24 weeks of treatment, the systolic blood pressure, diastolic blood pressure and pulse pressure difference in the case group were significantly lower than those in the control group (P<0.05).Compared with baseline, PWV values in the case group decreased by 0.63 m/s, 0.92 m/s, 1.66 m/s, and 2.24 m/s at 2, 4, 12, and 24 weeks, respectively. After 4, 12 and 24 weeks of treatment, PWV was significantly lower than that of control group, and the difference was statistically significant (P<0.05).After 12 weeks of treatment, ABI in case group (1.01±0.09) was significantly higher than that in control group (0.91±0.06), and the difference was statistically significant (P<0.05). After 24 weeks of treatment, ABI of the case group was further increased to 1.12±0.08, while that of the control group was 0.95±0.05, and the difference between the two groups was more significant (P<0.05).After 4 weeks of treatment, the arteriosclerosis index in the case group decreased significantly to 0.61±0.13, significantly lower than that in the control group (0.77±0.18, P=0.022), and decreased to 0.55±0.25 and 0.49±0.33 at 12 and 24 weeks of treatment, respectively. Compared with the control group, the differences were statistically significant (P=0.215 and P=0.110). After 24 weeks of treatment, the pulse pressure index of the two groups continued to decrease, and the case group (0.46±0.14) was significantly lower than the control group (0.56±0.11), the difference was statistically significant (P<0.001).Univariate Logistic regression analysis showed that the oral administration of Sakubactril valsartan sodium tablets was significantly associated with the decrease of PWV, arteriosclerosis index, pulse pressure index and the increase of ABI 

Compared with amlodipine, sacubatrotrivalsartan can effectively improve vascular endothelial function and arterial stiffness in hypertensive patients and delay the progression of atherosclerosis.